South Korea · Delayed Price · Currency is KRW curacle co.,ltd. Company Description
curacle co.,ltd., a bio-venture business, engages in the research and development of drugs for intractable vascular and metabolic diseases due to aging.
The company’s products in pipeline include CU06, a next-generation oral therapy, which completed phase 2a clinical trial for the treatment of diabetic macular edema; CU01, which completed Phase 2b clinical trial for Nrf2 activation and inhibition of TGF- β/Smad signaling; MT-101, a fully humanized Tie2 agonist antibody for the treatment of renal diseases; and MT-103, a bispecific antibody combining Tie2 agonist and anti-VEGF functions for the treatment of wAMD.
It also develops MT-105 for the treatment of irritable bowel diseases; MT-201, a non-bleeding anti-thrombotic antibody targeting PD-X; MT-202, a dual-mechanism therapy combining PD-X inhibition and Tie2 agonism for the treatment of acute ischemic stroke and heart failure with preserved ejection fraction; CU71, a next-generation neurovascular stabilizer for the treatment of alzheimer's disease; and CP01-R01, a first oral endothelial stabilizer–based candidate for companion animal CKD therapy.
In addition, the company develops SOLVADYS, proprietary oral small-molecule platform for the treatment of endothelial dysfunction; and EAGLES, a flagship platform of Maptics for next-generation biologics.
curacle co.,ltd. was incorporated in 2016 and is headquartered in Seoul, South Korea.
| Country | South Korea |
| Founded | 2016 |
| Industry | Biological Products, Except Diagnostic Substances |
| CEO | Jaehyeon Yoo |
Contact Details
Address: 23-1, Hyoryeong-ro Seoul, 06694 South Korea | |
| Phone | 82 2 3487 0077 |
| Website | curacle.com |
Stock Details
| Ticker Symbol | 365270 |
| Exchange | KOSDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | KRW |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jaehyeon Yoo | Chief Executive Officer |